Stay updated with breaking news from Markl Baum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Second Quarter 2023 and Recent Selected Highlights: Record revenues of $33.5 million, an increase of 44% over $23.3 million in the prior-year quarter and an increase of 28% over $26.1 million in...
VEVYE® is the First and Only Cyclosporine-Based Product Indicated for the Treatment of Both Signs and Symptoms of Dry Eye Disease with Efficacy Demonstrated After Four WeeksVEVYE® is the Only Water-Free Ophthalmic Product with Convenient Twice-Daily (BID) DosingNASHVILLE, Tenn. & HEIDELBERG, Germany--(BUSINESS WIRE)...
Transaction Includes U.S. and Canadian Commercial Rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, and Non-Prescription Brands FRESHKOTE® and Cationorm® PLUSNASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of a...
Harrow has signed agreements with affiliates of Santen Pharmaceutical to acquire certain US and Canadian commercial rights.
18.07.2023 - Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Novaliq GmbH, a German biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced an agreement under which Harrow will acquire the ... Seite 1